Belmont, MA, United States of America

Meena Meena

This inventor holds 2 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent. Top assignee: Wave Life Sciences Ltd.. Active years: 2024-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2024-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Meena Meena: Innovator in Chiral Design

Introduction

Meena Meena is a prominent inventor based in Belmont, MA (US). She has made significant contributions to the field of oligonucleotide design, particularly through her innovative work on chirally controlled oligonucleotides. Her research has the potential to impact various applications in biotechnology and medicine.

Latest Patents

Meena holds a patent for her invention titled "Chiral design." This invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, her chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. Additionally, it offers single site cleavage within a complementary sequence of a nucleic acid polymer.

Career Highlights

Meena is currently associated with Wave Life Sciences Ltd., where she continues to advance her research in the field of oligonucleotide technology. Her work is characterized by a commitment to innovation and excellence, contributing to the company's mission of developing transformative therapies.

Collaborations

Some of her notable coworkers include David Butler and Naoki Iwamoto, who collaborate with her on various projects within the company.

Conclusion

Meena Meena's contributions to chiral design and oligonucleotide technology exemplify her dedication to innovation in the scientific community. Her work not only enhances our understanding of nucleic acid interactions but also paves the way for future advancements in biotechnology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…